Company: AEMD
Filing Date: 2025-06-26
Form Type: 10-K
Source: 0001683168-25-004780
Chunk: 747

Company: AETHLON MEDICAL INC
Filing Date: 2025-06-26
Form: 10-K
Item: Item 4
Chunk 747
---
,302,617 of 2022 ATM Shares remained available for sale under the 2022 ATM Agreement.

Under
the 2022 ATM Agreement, Wainwright may sell the 2022 ATM Shares by any method permitted by law and deemed to be an “at the market
offering” as defined in Rule 415 promulgated under the Securities Act, including sales made directly on the Nasdaq Capital Market,
or on any other existing trading market for the 2022 ATM Shares. In addition, under the 2022 ATM Agreement, Wainwright may sell the 2022
ATM Shares in privately negotiated transactions with our consent and in block transactions. Under certain circumstances, we may instruct
Wainwright not to sell the 2022 ATM Shares if the sales cannot be effected at or above the price designated by us from time to time.

We
are not obligated to make any further sales of the 2022 ATM Shares under the 2022 ATM Agreement. The offering of the 2022 ATM Shares pursuant
to the 2022 ATM Agreement will terminate upon the termination of the 2022 ATM Agreement by Wainwright or us, as permitted therein.

The
2022 ATM Agreement contains customary representations, warranties and agreements by us, and customary indemnification and contribution
rights and obligations of the parties. We agreed to pay Wainwright a placement fee of up to 3.0% of the aggregate gross proceeds from
each sale of the 2022 ATM Shares. We also agreed to reimburse Wainwright for certain specified expenses in connection with entering into
the 2022 ATM Agreement.

 55 

Material Cash Requirements 

We expect our clinical trial
expenses for the planned oncology trials in Australia and India to increase for the foreseeable future. While these increases are primarily
related to trial activities, additional Hemopurifiers may also be manufactured to support the studies.

In addition, we have entered
into leases for our headquarters, laboratory and manufacturing facilities. We expect our rent payments to continue to increase for the
foreseeable future.

Future capital requirements
will depend upon many factors, including progress with pre-clinical testing and clinical trials, the number and breadth of our clinical
programs, the time and costs involved in preparing, filing, prosecuting, maintaining and enforcing patent claims and other proprietary
rights, the time and costs involved in obtaining regulatory approvals, competing technological and market developments, as well as our
ability to establish collaborative arrangements, effective commercialization, marketing activities